Evidence map›Paper›PMID 34572051›Full record

ArticleCells2021

Analysis of the Reversible Impact of the Chemodrug Busulfan on Mouse Testes.

Laura Thirouard, Hélène Holota, Mélusine Monrose, Manon Garcia, Angélique De Haze, Jean-Paul Saru, Françoise Caira, Claude Beaudoin, David H Volle

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Laura ThirouardINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.ORCID 0000-0003-4000-3073
Hélène HolotaINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.
Mélusine MonroseINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.
Manon GarciaINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.
Angélique De HazeINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.
Jean-Paul SaruINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.
Françoise CairaINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.
Claude BeaudoinINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.ORCID 0000-0002-4710-0610
David H VolleINSERM U1103, Université Clermont Auvergne, CNRS UMR-6293, GReD Institute, Team-Volle, F-63001 Clermont-Ferrand, France.
Centre National de la Recherche Scientifique · FR

Funding

Cancer Inserm C20010CSFondation ARC pour la recherche contre le cancer R16142CC)Fondation Recherche Médicale 17089CCFondation Recherche Médicale FDT202001010780
6 · The paper itself

Abstract

Spermatogenesis is a process within the testis that leads to the production of spermatozoa. It is based on a population of spermatogonial stem cells, which have the capacity to self-renew and to differentiate throughout life to ensure the functions of reproduction are maintained. Male fertility disorders are responsible for half of the cases of infertility in couples worldwide. It is well known that cancer treatments are associated with reversible or irreversible fertility disorders. Busulfan (Bu) is an alkylating agent that significantly inhibits spermatogenesis. The present study relied on a combination of in vivo and in vitro approaches as well as RNAseq analysis to characterize the effects of Bu, in which mouse testes were used as a model. An in silico analysis revealed that many of the Bu-modulated genes are potentially regulated by the SIN3 Transcription Regulator Family Member A (SIN3A) and E2F Transcription Factor (E2F) families of transcription factors. The results demonstrate that the deregulated genes function in processes related to the cell cycle, DNA repair, and cell death mechanisms, including the Tumor Protein 53 (TP53) pathway. This reinforces the role of the TP53 signaling pathway as a major player in Bu effects. In addition, Bu altered the patterns of mRNA accumulation for various genes in undifferentiated spermatogonia. This work provides significant insight into the kinetics and impacts of busulfan, which could pave the way for developing strategies to minimize the impact of chemodrugs and, thus, could lead to germ cell lineage regeneration following anticancer treatments.

Indexed as

AnimalsBusulfanDose-Response Relationship, DrugFemaleFertilityGene Expression RegulationImmunosuppressive AgentsMaleMiceMice, Inbred C57BLRNA-SeqTestisBusulfanImmunosuppressive Agentschemotherapydepletionregeneration and fertilityspermatogonial stem cell

Identifiers

PMID34572051
PMCPMC8472455
OpenAlexW3201585223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.